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Abstract: Background: To determine safety and efficacy of single cycle induction treatment with cisplat-
in/docetaxel and durvalumab/tremelimumab in stage III-IVB head and neck cancer. Methods: Patients
received a single cycle of cisplatin 30 mg/m² on days 1–3 and docetaxel 75 mg/m² on day 1 combined
with durvalumab 1500 mg fix dose on day 5 and tremelimumab 75 mg fix dose on day 5. Patients with
pathologic complete response (pCR) in the rebiopsy after induction treatment or at least 20% increase
of intratumoral CD8+ cell density in the rebiopsy compared with baseline entered radioimmunother-
apy with concomitant durvalumab/tremelimumab. The objective of this interim analysis was to analyze
safety and efficacy of the chemoimmunotherapy-induction treatment before radioimmunotherapy. Re-
sults: A total of 57 patients were enrolled, 56 were treated. Median pretreatment intratumoral CD8+
cell density was 342 cells/mm². After induction treatment, 27 patients (48%) had a pCR in the rebiopsy
and further 25 patients (45%) had a relevant increase of intratumoral CD8+ cells (median increase by
a factor of 3.0). Adverse event (AE) grade 3–4 appeared in 38 patients (68%) and mainly consisted of
leukopenia (43%) and infections (29%). Six patients (11%) developed grade 3–4 immune-related AE.
Univariate analysis computed p16 positivity, programmed death ligand 1 immune cell area and intra-
tumoral CD8+ cell density as predictors of pCR. On multivariable analysis, intratumoral CD8+ cell
density predicted pCR independently (OR 1.0012 per cell/mm², 95% CI 1.0001 to 1.0022, p=0.016). In
peripheral blood CD8+ cells, the coexpression of programmed death protein 1 significantly increased
especially in patients with pCR. Conclusions: Single cycle induction treatment with cisplatin/docetaxel
and durvalumab/tremelimumab is feasible and achieves a high biopsy-proven pCR rate.
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ABSTRACT
Background To determine safety and efficacy of single 
cycle induction treatment with cisplatin/docetaxel and 
durvalumab/tremelimumab in stage III- IVB head and neck 
cancer.
Methods Patients received a single cycle of cisplatin 
30 mg/m² on days 1–3 and docetaxel 75 mg/m² on 
day 1 combined with durvalumab 1500 mg fix dose 
on day 5 and tremelimumab 75 mg fix dose on day 5. 
Patients with pathologic complete response (pCR) in 
the rebiopsy after induction treatment or at least 20% 
increase of intratumoral CD8+ cell density in the rebiopsy 
compared with baseline entered radioimmunotherapy with 
concomitant durvalumab/tremelimumab. The objective of 
this interim analysis was to analyze safety and efficacy 
of the chemoimmunotherapy- induction treatment before 
radioimmunotherapy.
Results A total of 57 patients were enrolled, 56 were 
treated. Median pretreatment intratumoral CD8+ cell 
density was 342 cells/mm². After induction treatment, 27 
patients (48%) had a pCR in the rebiopsy and further 25 
patients (45%) had a relevant increase of intratumoral 
CD8+ cells (median increase by a factor of 3.0). Adverse 
event (AE) grade 3–4 appeared in 38 patients (68%) and 
mainly consisted of leukopenia (43%) and infections 
(29%). Six patients (11%) developed grade 3–4 immune- 
related AE. Univariate analysis computed p16 positivity, 
programmed death ligand 1 immune cell area and 
intratumoral CD8+ cell density as predictors of pCR. On 
multivariable analysis, intratumoral CD8+ cell density 
predicted pCR independently (OR 1.0012 per cell/mm², 
95% CI 1.0001 to 1.0022, p=0.016). In peripheral blood 
CD8+ cells, the coexpression of programmed death 
protein 1 significantly increased especially in patients 
with pCR.
Conclusions Single cycle induction treatment with 
cisplatin/docetaxel and durvalumab/tremelimumab is 
feasible and achieves a high biopsy- proven pCR rate.
INTRODUCTION
Immune checkpoint inhibitors directed 
against programmed death protein 1 (PD-1) 
have become standard treatment in patients 
with recurrent and/or metastatic head and 
neck squamous cell carcinoma (HNSCC).1 2 
A first phase Ib trial proved the feasibility of 
the PD-1 inhibitor pembrolizumab in combi-
nation with radiochemotherapy with weekly 
administration of cisplatin in locally advanced 
tumors.3 The ongoing phase III trials 
Keynote-412 and Javelin head and neck 100 
add anti- PD(L)1 agents to standard radio-
chemotherapy with three administrations 
of high- dose cisplatin in locally advanced 
tumors. However, recently it was reported in 
a press release that Javelin head and neck 100 
will not meet its primary endpoint.
Beside primary radiochemotherapy, the 
strategy of induction chemotherapy followed 
by radio(chemo)therapy has become a treat-
ment option for laryngeal cancer.4 However, 
when this strategy was expanded to other 
locations in the head and neck, random-
ized trials failed to prove a survival benefit 
compared with radiochemotherapy alone.5 
In more recent trials using induction chemo-
therapy, excellent responders were identified 
after three cycles and subsequently treated 
with dose and volume- reduced radiotherapy 
in order to minimize late toxicity.6 7
The CheckRad- CD8 study was conducted 
to develop an efficient single cycle induction 
therapy, which allows patient selection for a 
further chemotherapy- free treatment based 
on pathologic response evaluation. Induction 
2 Hecht M, et al. J Immunother Cancer 2020;8:e001378. doi:10.1136/jitc-2020-001378
Open access 
treatment consisted of cisplatin, docetaxel, durvalumab 
and tremelimumab. Patients with pathologic response 
entered definitive radiation therapy combined with 
durvalumab and tremelimumab followed by durvalumab 
maintenance, here called radioimmunotheapy.
The combination of durvalumab with platinum- based 
chemotherapy was studied in the phase III CASPIAN trial 
in extensive- stage small cell lung cancer. In this trial, the 
addition of durvalumab increased overall survival (OS) 
without relevant increase in toxicity.8 The combination 
of durvalumab and tremelimumab with chemotherapy 
was studied in the Canadian phase IB IND226 trial 
mainly in patients with lung cancer. This was the first trial 
that proved the feasibility of a quadruple combination 
consisting of durvalumab and tremelimumab in combina-
tion with platinum- doublet chemotherapy and provided 
first dose recommendations.9
In this interim analysis of the CheckRad- CD8 trial the 
safety, antitumor activity and biological response of this 
single cycle induction treatment were studied in locally 
advanced HNSCC. To our knowledge, this is the first 
report on safety and antitumor activity of a combina-
tion scheme consisting of chemotherapy, programmed 
cell death ligand 1 (PD- L1) and cytotoxic T lymphocyte- 
associated antigen 4 (CTLA-4) antagonists.
MATERIAL AND METHODS
Trial design and treatment
CheckRad- CD8 is a multicenter open- label phase II 
study with a single treatment arm in patients with locally 
advanced HNSCC. Eligible patients received a single cycle 
of induction treatment in week 1 with cisplatin 30 mg/
m² body surface area (BSA) on days 1–3 and docetaxel 
75 mg/m² BSA on day 1. In patients with impaired renal 
function, cisplatin could be replaced by carboplatin AUC 
1.5 on days 1–3. The immune checkpoint inhibitors 
tremelimumab (anti- CTLA4) at a fixed dose of 75 mg and 
durvalumab (anti- PDL1) at a fixed dose of 1500 mg were 
both administered on day 5. Restaging was performed in 
week 4 with contrast- enhanced CT or MRI of the neck 
and endoscopy with representative rebiopsy. The density 
of intratumoral CD8+ cells was assessed via immunohis-
tochemistry and digital image analysis before treatment 
and in the rebiopsy at the restaging. Biopsies were always 
taken of the primary tumor and not of the lymph nodes. 
Patients with at least stable disease in imaging according to 
RECIST 1.1 criteria and an increase of intratumoral CD8+ 
cells of at least 20% compared with baseline continued 
with trial treatment and entered radioimmunotherapy. 
Also patients with no remaining tumor in a sufficiently 
covered tumor bed in the rebiopsy (pathologic complete 
response, pCR) continued with trial treatment. Coverage 
of a former tumor bed was considered to be sufficient, if a 
relevant resorptive inflammation (macrophages, neutro-
phil granulocytes, lymphocytes) in conjunction with 
granulation and scar tissue could be found in post ther-
apeutic biopsies. To ensure that minute residual tumor 
parts were not overseen, multiple section levels were eval-
uated (six levels per specimen). These patients received 
radiotherapy up to 70 Gy in 35 fractions with additional 
three cycles of combined durvalumab/tremelimumab, 
followed by 8 cycles of durvalumab monotherapy admin-
istered every fourth week. Patients not meeting these 
criteria receive standard radiochemotherapy outside the 
trial.
Trial oversight
The trial was registered with  ClinicalTrials. gov (identi-
fier: NCT03426657). All patients gave written informed 
consent before the first study procedures were performed.
Patients
Eligible patients had histologically confirmed HNSCC 
stage III- IVB of the oral cavity, oropharynx, hypopharynx 
or supraglottic larynx. Main inclusion criteria were an 
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status of 0–1, adequate bone marrow, hepatic and 
renal function and provided tumor tissue for CD8+ cell 
assessment in central pathology. Main exclusion criteria 
were prior surgical procedures or systemic treatments of 
the HNSCC, autoimmune diseases and history of radio-
therapy to the head and neck region.
Endpoints and assessments
Co- primary endpoints of the CheckRad- CD8 trial are the 
feasibility of induction chemoimmunotherapy followed 
by radioimmunotherapy and the predictive character 
of changes of the intratumoral CD8+ immune cells. 
Key secondary endpoints are OS and progression- free 
survival. In this interim analysis, the safety and efficacy of 
this single cycle induction treatment before radiotherapy 
were studied together with first biomarker analyses. 
Toxicity was evaluated weekly from study inclusion until 
after the restaging assessments (before radiotherapy) 
using the Common Terminology Criteria for AE (CTCAE 
version 4.03). Pathologic response was assessed centrally 
in the Institute of Pathology Erlangen and scored as rate 
of patients without residual tumor in rebiopsy (CR). 
The intratumoral CD8+ cell density was analyzed quan-
titatively. Response by imaging was evaluated according 




Immunohistochemistry was performed on 2 µm whole 
slide sections on a Ventana Benchmark Ultra autostainer 
(Ventana) according to accredited staining protocols 
(https://www. dakks. de/ en) using the following anti-
bodies: PD- L1 (closed SP263 assay, Ventana; companion 
diagnostic assay for durvalumab/tremelimumab), CD8 
(C8/144B, mouse monoclonal; ThermoFisher- Scientific; 
dilution 1:100). All sections were counterstained with 
hematoxylin. PD- L1 positive immune cells (ICs) and 
tumor cells (TCs) were scored by two systematically 
trained pathologists according to the distributor’s PD- L1 
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scoring algorithm (‘AstraZeneca’/Durvalumab algo-
rithm). PD- L1 positive TCs were scored as percentage of 
the PD- L1 positive TC area per total TC area (%; positive 
tumor cell area/total tumor cell area; Ventana TC- score). 
PD- L1 positive ICs were scored as proportion of the area 
occupied by PD- L1 positive tumor- associated IC per total 
area occupied by tumor- associated IC (%; area occupied 
by positive IC/total area occupied by IC; Ventana IC- area 
score). Whole tissue sections stained for CD8 were scanned 
using the Panoramic P250 slide scanner (3DHistech) and 
imported into QuPath (QuPath v0.2.0).10 Regions of 
interest (ROI; tumor cell area, tumor- associated stroma 
area, total tumor area) were annotated manually by an 
experienced pathologist, and cells were quantified auto-
matically with the ‘Positive Cell Detection’ tool for immu-
nohistochemically stained slides. CD8+ cytotoxic T cells 
were quantified absolutely per millimeter square in all 
ROIs.
Multicolor flow cytometry
Whole blood samples of the patients were collected and 
analyzed by multicolor flow cytometry according to our 
previously published modularly immunophenotyping 
(IPT) protocols.11 12 Direct antibody staining of whole 
blood samples was performed without previous isolation 
of blood mononuclear cells, which allows the detection 
of all types of circulating ICs, including granulocytes. 
IPT was performed within 24 hours after the collection 
of whole blood. Data were acquired on a Gallios Flow 
Cytometer (Beckman Coulter, Brea, California, USA) 
in the standard filter configuration. The Kaluza Flow 
Analysis Software (Beckman Coulter) was used for data 
analyses.
Statistical analysis
The current interim analysis is an unplanned exploratory 
analysis, which was performed after an unexpected high 
rate of pCRs was detected in the first preplanned safety 
interim analysis after 30 patients.
The Wilcoxon- Mann- Whitney test and the Wilcoxon 
signed- rank test were used to compare continuous vari-
ables, that is, intratumoral CD8+ cells and PD- L1, in 
dependence of treatment response and HPV status, and 
between different time points of measurement, respec-
tively. Fisher’s exact test was used to identify categorical 
predictive parameters for pCR in univariable analyses. In 
the multivariable analysis, logistic regression was applied 
considering all factors with a univariable p value of <0.1 to 
identify independent prognostic factors for pCR.
Statistical analyses were carried out using the soft-
ware packages R, NCSS and GraphPad Prism V.8.1.2 
(GraphPad Software, California, USA).
RESULTS
Patient characteristics and treatment parameters
Fifty- seven patients were enrolled from September 2018 to 
December 2019 in seven German centers. One patient did 
not receive any dose of either drug due to tumor bleeding 
and was excluded from all analyses. Baseline characteris-
tics are given in table 1. As the tumor, node, metastases 
(TNM) seventh edition was replaced during the trial, all 
tumor stages were adapted to the eighth edition (UICC 
stage according to the TNM seventh edition is given in 
the online supplemental table 1). PD- L1 status was scored 
as percentage of total tumor cell area with the previously 
established cut- off value of 25% for durvalumab±tremeli-
mumab in HNSCC.13 PD- L1 was high (area ≥25%) on TCs 
in 10 patients (18%) and on ICls in 21 patients (38%). Six 
patients (11%) received carboplatin instead of cisplatin. 
Two patients (4%) received only induction chemotherapy 
without immune checkpoint inhibitors due to AE (one 
infection and one elevated transaminases).
Safety analyses
Adverse events (AEs) occurring between study inclusion 
and the end of the restaging assessments are listed in 
table 2. Among all patients enrolled, 52 (93%) experi-
enced an AE of any grade. There were 37 patients (66%) 
who experienced a grade 3 AE and 7 patients (13%) who 
experienced a grade 4 AE, with 38 patients (68%) having 
at least one grade 3–4 AE (95% CI 54% to 80%). Most 
common AE grade 3–4 were leukopenia in 24 patients 
(43%) and infections in 16 patients (29%). The median 
duration of AEs grade 3–4 was 7 days. Detailed data 
about the duration of toxicities on patients’ level are 
shown in figure 1. Six patients (11%) developed grade 
3–4 immune- related AE (irAE) including hepatitis in 
three patients, diarrhea in two patients and pancreatitis 
in one patient. One additional patient developed grade 
3 elevated transaminases without prior immune check-
point inhibitors. Study treatment was discontinued after 
the restaging assessment due to toxicity in six patients, 
including the above- mentioned three cases of hepatitis, 
one infection grade 4, one immune- related diarrhea 
grade 3 and one nephritis grade 2. These patients were 
subsequently treated with definitive radiotherapy with 
simultaneous chemotherapy or cetuximab outside the 
study protocol. Immune- suppressive medication for AE 
management was administered in eleven patients (20%). 
Reasons for systemic corticosteroids were the six grade 
3–4 irAE mentioned above and further three cases of 
grade 2 diarrhea and one case of grade 2 nephritis. One 
patient received topical corticosteroids due to exanthema 
grade 1. The patient with hepatitis grade 4 was addition-
ally treated with mycophenolat- mofetil.
Efficacy outcomes
Restaging assessment with panendoscopy and rebiopsy 
of the primary tumor was performed in 55 of 56 treated 
patients (see figure 2A). The major finding of this trial 
was that 27 patients (48%; 95% CI 35% to 62%) had 
no residual primary tumor in the rebiopsy (pCR). In 
the other 28 patients with residual primary tumor, 25 
patients (45%) had an intratumoral CD8+ cell increase 
of at least 20%, which is the cut- off value for further study 
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treatment. In three patients (5%) CD8+ cells decreased. 
Taken together, 52 patients (93%) fulfilled the criteria for 
further study treatment. Six patients had to be excluded 
from further study treatment due to treatment- related AE 
and four patients decided for alternative or no further 
treatment. Finally, 42 patients (75%) entered radioimmu-
notherapy within the trial.
Radiographic treatment response was evaluated 
according to RECIST 1.1 criteria (see figure 2B). In 40 
evaluable patients, one (3%) had a complete response 
(CR), 16 (40%) had partial responses (PR) and 23 (58%) 
stable diseases. There was no progressive disease. When 
the responses are compared with the preinduction intra-
tumoral CD8+ cell densities, 11 of the 17 responding 




Intratumoral CD8+ cell density and PD- L1 were prospec-
tively analyzed in the preinduction and postinduction 
tissue. Tissue was available preinduction in all 56 treated 
patients and postinduction in 55 patients. Preinduction 
and postinduction histologic findings of representative 
patients with residual tumor (without and with immuno-
logical response) and pCR are shown in figure 3A. The 
median pretreatment intratumoral CD8+ cell density 
was 342 cells/mm² (range 22–3922 cells/mm²). The 
preinduction intratumoral CD8+ cell density was signifi-
cantly higher in patients who developed a pCR than in 
patients with residual tumor (figure 3B). The prein-
duction PD- L1 tumor cell area (TCarea) did not differ 
significantly between patients with pCR and residual 
tumor (figure 3C). In contrast, the preinduction PD- L1 
immune cell area (ICarea) was significantly higher in 
cases with pCR (figure 3D). In patients with residual 
tumor, the intratumoral CD8+ cell density increased after 
induction treatment (figure 3E) by a median factor of 
3.0. In contrast to tumor cells, induction treatment led 
to a significant increase of PD- L1 expression on immune 
cells (figure 3F,G). The raw data of these analyses are 
displayed in the online supplemental table 2. Human 
Table 1 Patient characteristics of treated patients
No. (n=56) %
Age (median, SD) 59.0±8.6 years
Sex
  Male 45 80
  Female 11 20
Zubrod performance status
  0 41 73
  1 12 21
  Unknown 3 5
Primary tumor site
  Oral cavity 7 13
  Oropharynx 27 48
  Hypopharynx 12 21
  Larynx 10 18
T category
  T1 5 9
  T2 6 11
  T3 13 23
  T4 32 57
N category
  N0 13 23
  N1 13 23
  N2 23 41
  N3 7 13
UICC stage (according to TNM eighth edition)
  II* 3 5
  III 21 38
  IVA 20 36
  IVB 12 21
Tobacco smoking status
  Current smoker 21 38
  Former smoker 22 39
  Never smoker 10 18
  Unknown 3 5




  Tumor cells (TC area)
  <25% 46 82
  ≥25% 10 18
  Immune cells (IC area)
  <25% 35 63
  ≥25% 21 38
  Algorithm positivity
  Positive 27 48
  Negative 29 52
Continued
No. (n=56) %
HPV status all tumors (p16 positivity)
  Positive 17 30
  Negative 39 70
Human papilloma virus (HPV) status, Oropharynx only (p16 
positivity) (n=27)
  Positive 14 52
  Negative 13 48
*These patients were included before the TNM transition to the 
eighth edition.
TNM, tumor, node, metastases.
Table 1 Continued
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papilloma virus (HPV) positive tumors had a significantly 
higher preinduction CD8+ cell density compared with 
HPV- negative tumors (online supplemental figure 1A). 
The PD- L1 TCarea did not differ significantly in HPV 
positive and negative tumors. In contrast, HPV- positive 
tumors showed a significantly increased PD- L1 ICarea 
(online supplemental figure 1B,C).
Univariable analyses identified p16 positivity, PD- L1 
IC area and intratumoral CD8+ cell density as signifi-
cant positive predictors of pCR (online supplemental 
table 3). Additionally, a significant correlation between 
the amount of PD- L1+ with CD8+ ICs was found (PD- L1 
ICarea ≥25%: median 619 CD8+ cells/mm² vs PD- L1 
ICarea <25%: median 264 CD8+ cells/mm², p=0.0009). 
As this correlation has also been described before14 and 
recently also the functional role of the expression of 
PD- L1 on CD8+ lymphocytes was published in detail,15 
PD- L1 on ICs was excluded from the multivariable anal-
ysis. In the multivariable analysis, intratumoral CD8+ cell 
density remained an independent predictor of pCR (OR 
1.0012 per cell/mm², 95% CI 1.0001 to 1.0022, p=0.016), 
whereas p16 positivity lost its statistical significance.
Multicolor flow cytometry
Due to this crucial role of the CD8+ cytotoxic T cells in 
the tumor, this cell type was also studied in the peripheral 
blood. The number of CD8+ cytotoxic T cells showed no 
significant differences in patients with pCR or residual 
tumor and did not change significantly after induction 
treatment (figure 2H). However, PD-1 coexpression 
significantly increased after induction treatment espe-
cially in patients with pCR (figure 2J).
Table 2 Adverse events
Adverse event
Any grade Grade 3 Grade 4
No. % No. % No. %
Total patients (n=56) with 
an event
52 93 37 66 7 13
Infections* 38 68 14 25 2 4
Alopecia 38 68 0 0
Nausea 37 66 1 2 0
Fatigue 36 64 2 4 0
Leukopenia 33 59 20 36 4 7
Diarrhea 28 50 2 4 0
Xerostomia 21 38 0 0
Dysphagia 19 34 6 11 0
Vomiting 16 29 1 2 0
Pain 14 25 0 0
Pruritus 13 23 0 0
Vertigo 12 21 1 2 0
Thrombopenia 12 21 0 0
Stomatitis 12 21 0 0
Exanthema 9 16 0 0
Constipation 9 16 0 0
Hypokalemia 6 11 0 0
Renal insufficiency 6 11 0 0
Tumor bleeding 5 9 1 2 0
Increased transaminases/
hepatitis
4 7 3 5 1 2
Dysgeusia 3 5 1 2 0
Increased lipase/
pancreatitis
1 2 1 2 0
Gout 1 2 1 2 0
Pleural effusion 1 2 1 2 0
Deep vein thrombosis 1 2 1 2 0
Adverse events of treated patients independent of relationship 
to treatment occurring in at least 10% of the patients and all 
adverse events grade 3–4.
*Reasons for infections (any grade) noticed more than once were 
pneumonia (n=2), wound infections (n=2) and gastric feeding 
tube infections (n=2).
Figure 1 Duration of adverse events (AEs) ≥grade 3. The 
swimmer plot presents the duration of AE ≥grade 3 separated 
in conventional AE and immune- related AE (irAE) on patients 
level. Each bar represents an individual patient. Toxicity was 
assessed from study inclusion until the end of the restaging 
period (day before the first fraction of radiotherapy) or the 
safety follow- up (before subsequent treatment). *This patient 
denied further treatment after complete response (CR); after a 
follow- up of 12 months, the tumor is still in CR.
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DISCUSSION
The results of the CheckRad- CD8 trial support the feasi-
bility of the combination of docetaxel/cisplatin with 
durvalumab/tremelimumab as single cycle induction 
treatment in locally advanced HNSCC. The feasibility 
of radiotherapy combined with durvalumab/tremelim-
umab, including the whole safety of all the treatment, 
will be studied in a future analysis. Grade 3–4 AE mainly 
consisted of leukocytopenia and infections. This may be 
prevented by prophylactic use of G- CSF, which was not 
part of the study protocol. However, prophylactic G- CSF 
has to be discussed critically, as it may also increase 
myeloid- derived suppressor cells leading to impaired 
tumor control.16 The incidence of irAE grade 3–4 in 
11% of the patients was in the expected range and the 
events were treated effectively by immune- suppressive 
treatment. The first study that established data on feasi-
bility of durvalumab and tremelimumab in combination 
with platinum- doublet chemotherapy was the Canadian 
IND226 trial.9 In this trial, patients with different tumors, 
mainly non–small cell lung cancer, received durvalumab 
and tremelimumab at different dose levels in combination 
with chemotherapy. The studied chemotherapy regimens 
included pemetrexed/platinum, gemcitabine/platinum, 
etoposide/platinum and nab- paclitaxel/carboplatin, but 
not the scheme of the CheckRad- CD8 trial docetaxel/
platinum. Treatment was feasible up to the highest dose 
level of 1500 mg durvalumab q3w (every three weeks) 
and 75 mg tremelimumab q3w (up to four doses of 
tremelimumab). The frequency of irAE ≥grade 3 was 21% 
compared with 11% in the CheckRad- CD8 trial. As this 
analysis of the CheckRad- CD8 trial focuses on the period 
until the end of the restaging assessments, additional late 
irAE might increase the rate of irAE. In the IND226 study, 
irAE ≥grade 3 mainly consisted of diarrhea (9%), which 
also appeared in the CheckRad- CD8 trial (4%). The most 
frequent irAE ≥grade 3 in CheckRad- CD8 was hepatitis 
(5%), which also appeared in 3% in IND226. The studied 
induction treatment resulted in a high rate of biopsy- 
proven pCR in 48% of the patients after only a singe cycle 
of induction chemoimmunotherapy. In further 45% of 
the patients, intratumoral CD8+ cells increased, which 
has previously been described as predictor of treatment 
response to PD-1 antagonists.14 Patient selection was 
based on biopsies and not imaging, as the time period of a 
single cycle induction treatment is too short to allow suffi-
cient tumor shrinkage. The pathologic response assess-
ment in a rebiopsy opens the opportunity to study new 
pathologic parameters besides pCR as possible predictive 
values. A similar approach was performed in a study with 
neoadjuvant pembrolizumab using tumor necrosis, giant 
cells and histiocytic reaction as response criteria.17
The rate of clinical complete responses after three 
cycles of docetaxel, cisplatin and 5- fluorouracil 5FU (TPF) 
ranges from 17% to 43% in phase III trials with unselected 
patients.18–22 However, data about biopsy- proven pCR rates 
after induction chemotherapy are limited. In a Spanish 
phase III trial, biopsies were performed in a quarter of 
the 382 randomized patients, and a biopsy- proven pCR 
was found in 42% of the patients after three cycles of 
paclitaxel/cisplatin/5FU arm compared with 23% in the 
cisplatin/5FU arm.19 In a GORTEC trial, biopsies were 
performed in half of the 213 randomized patients, and a 
biopsy- proven pCR was found in 64% of the patients after 
three cycles TPF compared with 36% in the cisplatin/5FU 
arm.20 In a phase II trial with three cycles of TPF induc-
tion before planned surgery, the pCR rate of the primary 
tumor was 33%.23 A limitation of the CheckRad- CD8 trial 
is that only biopsies and not complete surgical specimens 
were available, which probably has a reduced sensitivity 
in the detection of residual TCs and may lead to an over-
estimation of the pCR rate. Taken together, the efficacy 
of only a single cycle induction treatment with cisplatin/
Figure 2 Consolidated Standards of Reporting Trials 
(CONSORT) diagram and treatment response. (A) CONSORT 
diagram including pathologic treatment response. pCR, 
pathologic complete response. (B) Radiographic response 
in dependence of baseline intratumoral CD8+ cell density 
(CD8↑, preinduction CD8 density above median; CD8↓, 
preinduction CD8 density below median). The radiographic 
response was evaluated according to RECIST 1.1 criteria. 
Tumor responses were measured at baseline and at the 
restaging before radiotherapy. The values shown are the 
percentage change in the sum of longest diameters. Each bar 
represents one patient. CR, complete response; PR, partial 
response; SD, stable disease.
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Figure 3 Histological parameters associated with treatment response. HE and immunohistochemical CD8 staining (brown) 
of representative patients. Residual tumors (ReTu) without immunologic response typically showed no tumor- infiltrating 
immune cells preinduction and postinduction neither in the HE nor in the CD8 staining. In residual tumors with immunological 
response, an increase of intratumoral immune cells is typically found both in HE and CD8 staining postinduction compared 
with preinduction. In patients who developed pCR, tumor- infiltrating immune cells are typically present preinduction and even 
increase post- induction. Comparison of (B) intratumoral CD8+ cell density, (C) programmed cell death ligand 1 (PD- L1) tumor 
cell area (TC area) and (D) PD- L1 immune cell area (IC area) in patients with residual tumor (ReTu) and pathologic complete 
response (pCR). Changes of (E) intratumoral CD8+ cell density, (F) PD- L1 TC area and (G) PD- L1 IC area before and after 
induction treatment in patients with residual tumor. (H) Peripheral blood concentration of CD8+ cells before and after induction 
treatment in patients with ReTu and pCR. (J) PD-1 coexpression of peripheral blood CD8+ cells before and after induction 
treatment in patients with ReTu and pCR.
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docetaxel and durvalumab/tremelimumab seems to be at 
least comparable with three cycles of TPF induction.
Two phase II trials containing 21 and 28 patients, respec-
tively, studied a single dose of pembrolizumab before 
planned surgery in locally advanced HNSCC.17 24 A limita-
tion of the comparison of these trials with the Check-
Rad- CD8 trial is that in these trials complete surgical 
specimens were available compared with biopsies in 
CheckRad- CD8. However, as altogether only one pCR 
appeared in these two trials, the single agent induction 
seems to be less effective in inducing pCR compared with 
the combined induction therapy of the CheckRad- CD8 
trial. In the IMCISION trial containing 12 patients, 
treatment consisted of two doses of nivolumab alone 
or in combination with a single dose of ipilimumab in 
a neoadjuvant setting.25 Their findings of one ‘near 
complete response’ in the monotherapy arm and two 
‘near complete responses’ in the combined arm, together 
with an increased immune- related gene expression in 
the combined arm, favor a combined approach. In the 
CIAO trial, 28 patients received two cycles of neoadju-
vant durvalumab either alone or in combination with 
tremelimumab.26 Two of 25 patients (8%) developed a 
pCR. Interestingly, three patients who received subse-
quent induction chemotherapy all developed pCR of 
their primary tumor, which favors induction treatments 
of combined chemoimmunotherapy. Similar approaches 
were also studied in non–small cell lung cancer. Two 
preoperative doses of nivolumab induced pCR of the 
primary tumor in 3e of 20 resected tumors (15%).27
In the phase III EAGLE trial, both durvalumab alone 
and durvalumab with tremelimumab failed to prove a 
significant improvement of OS compared with second line 
chemotherapy in recurrent and/or metastatic HNSCC.13 
However, the 1- year survival rate of durvalumab with 37% 
was comparable to second line trials with nivolumab with 
36% or pembrolizumab with 37%, whereas the 1- year 
survival rate of durvalumab with tremelimumab was only 
30%.2 13 28 The results of the phase III KESTREL trial 
with a durvalumab/tremelimumab combination in first- 
line treatment are still outstanding. As tremelimumab 
enhances T- cell priming in an early phase, the combi-
nation with single PD- (L)1 agents that only can release 
a pre- existing immune reaction may not be efficient. 
Nevertheless, the combination with cell death inducing 
agents as chemotherapy or radiotherapy may release a 
real benefit of tremelimumab.29 30
The median pretreatment intratumoral CD8+ cell 
density of 342 cells/mm² in the CheckRad- CD8 trial is in 
line with previous reports with ranges between median 
cell densities of 220/mm² in the tumor center and 545/
mm² in the invasive margin.31 The presented results of 
the CheckRad- CD8 trial emphasize the value of the 
baseline intratumoral CD8+ cell density as independent 
predictor for pCR after induction chemoimmunotherapy. 
These findings are in line with previous reports on the 
predictive role of intratumoral CD8+ cells in PD-1 inhib-
itor monotherapy.14 However, in the CIAO trial using 
immunotherapy without chemotherapy, no predictive 
value of intratumoral CD8+ cell density was reported.26 
Tumor- infiltrating immune cells also have a prognostic 
value in chemoradiotherapy of HNSCC, whereas their 
role in chemotherapy alone is not clear.32 33 In the Check-
Rad- CD8 trial, patients with residual tumor had a median 
increase of intratumoral CD8+ cell density by a factor of 
3.0. In the CIAO trial, CD8 density also increased, but 
only by a factor of 1.3 for durvalumab monotherapy and 
a factor of 1.2 for durvalumab combined with tremeli-
mumab.26 The reason for this more intense immune 
activation in the CheckRad- CD8 trial is probably the 
combination with chemotherapy as especially docetaxel 
is expected to have immune- modulating properties.34 A 
limitation of the CD8 measurement and PD- L1 analyses 
is that intratumoral heterogeneity cannot be evaluated as 
only biopsies were analyzed in the CheckRad- CD8 trial. 
Regarding the staining method and subsequent patho-
logic evaluation, CD8+ cells have already been validated 
for colon cancer.35
Recent phase III trials with PD-1 inhibitors in HNSCC 
typically use PD- L1 on tumor cells or combined on TCs 
and ICs as predictive marker.1 2 28 In the CheckRad- CD8 
trial, only PD- L1 on ICs and not on TCs was a predictor of 
pCR in the univariate analysis. Interestingly, this finding 
of a better predictive value of PD- L1 on immune cells 
compared with TCs has also been described before for 
PD-1 inhibitor monotherapy.36
HPV- positive tumors are typically identified via p16 
immunohistochemistry and have superior prognosis, 
especially if treated with radiochemotherapy or induction 
treatment followed by radiochemotherapy,37 38 which has 
been attributed to significantly higher immune responses 
especially to HPV- positive oropharyngeal HNSCC.39 This 
effect was also found in a recent phase IB trial when 
radiochemotherapy was combined with pembrolizumab 
in locally advanced HNSCC.3 In the CheckRad- CD8 
trial, p16 positive tumors had a higher CD8+ cell density 
and higher PD- L1 immune cell area compared with p16 
negative tumors. Increased densities of tumor- infiltrating 
immune cells in p16- positive tumors have also been 
reported previously.40 Despite this increased immune 
cell infiltration in p16- positive tumors, the immune cell 
composition of T- cell subsets is similar to p16- negative 
tumors, but B- cells seem to differ in both tumor types.41 In 
a recent meta- analysis, patients with p16- positive HNSCC 
treated with immune checkpoint inhibitors had a favor-
able OS.42 This is in line with the CheckRad- CD8 trial, as 
p16 positivity had a positive predictive value for pCR after 
induction chemoimmunotherapy.
Another new finding of this trial is that, especially in 
patients with pCR, the coexpression of PD-1 increases on 
peripheral blood CD8+ cytotoxic T cells. This is probably 
not a sign of cell exhaustion, but indicates the expan-
sion of cell subpopulations with high capacity for tumor 
recognition.43
In conclusion, single cycle of induction treatment with 
cisplatin/docetaxel and durvalumab/tremelimumab is 
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feasible. This treatment achieves a high rate of biopsy- 
proven pCR of 48%. The pre- therapeutic intratumoral 
CD8+ cell density is the most valuable predictive factor 
for pCR. These results encourage the clinical develop-
ment of induction treatments with combined chemoim-
munotherapy in HNSCC.
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